Leal Therapeutics LLC

▎药明康德内容团队编辑 David Baker博士联合创建，新锐完成2000万美元种子轮融资 Archon Biosciences今日宣布走出隐匿模式，并完成2000万美元种子轮融资。该公司的技术平台利用了人工智能（AI）驱动的计算蛋白设计方面的进展。此项技术因在创建具有特定功能的新蛋白方面的能力而被授予2024年诺贝尔化学奖。诺奖得主，华盛顿大学的David Baker博士是该公司的联合创始人之一。 Archon Biosciences致力于设计一种称为抗体笼（antibody cage，AbC）的全新生物制品类型。它由抗体和一组在大自然中不存在的AI生成蛋白结构域组合而成。对AbC结构的精准控制可以调节其在体内的分布方式以及与细胞靶点的高特异性和高效性相互作用。 Archon将生成式蛋白设计直接应用于药物开发，不仅设计，而且迅速制造出新分子实体以供临床前研究。AbC的设计结合了现成的抗体和计算设计的结合蛋白，这些蛋白通过自组装，构成精确的几何纳米结构。由于其独特的几何形状，AbC在体内的行为和与靶点的相互作用不同于传统的生物制品，能够更好地控制如靶点结合和生物分布等功能特性。 1.15亿美元助力潜在“first-in-class”小分子疗法获得临床概念验证 Axonis Therapeutics今日宣布成功完成超额认购的1.15亿美元A轮融资。获得资金将用于推进其主要候选药物AXN-027的临床概念验证。AXN-027是一种潜在“first-in-class”的口服小分子药物，旨在增强KCC2的功能。KCC2是中枢神经系统中的主要氯离子转运蛋白，对抑制性神经信号传递至关重要，AXN-027的适应症包括癫痫和疼痛。本轮融资还将支持新一代靶向KCC2化合物的开发，覆盖癫痫、疼痛及包括精神类和神经发育类疾病在内的其他适应症。 开发下一代核药，新锐完成7650万美元A轮融资 Blue Earth Therapeutics今日宣布完成7650万美元A轮融资。获得的资金将帮助该公司进一步推进其处于临床阶段的前列腺特异性膜抗原（PSMA）靶向放射性配体疗法的开发。该公司的放射性配体分子由四个不同的结构域组成。第一个结构域是靶向PSMA的配体，连接有两个可标记的结构域，这些结构域可以用治疗性同位素如177Lu或225Ac标记成为放射性配体疗法。所有这些成分通过可调节的连接子相连，用于调控疗法的重要药代动力学特性。 目前该公司基于177Lu的放射性配体疗法已经进入1期临床试验，用于治疗前列腺癌患者。 针对中枢神经系统疾病，新锐完成4500万美元融资 Leal Therapeutics今日宣布完成4500万美元融资。获得资金将用于推进该公司针对中枢神经系统疾病患者的反义寡核苷酸（ASO）和小分子疗法产品管线。Leal的主要在研项目包括LTX-002，一款治疗遗传性或散发性肌萎缩侧索硬化（ALS）患者的ASO疗法，以及LTX-001，一款针对精神分裂症患者的小分子药物。该公司计划在2024年底前提交LTX-002和LTX-001的IND申请，并在2025年初启动首次人体临床试验。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料： [1] Archon Biosciences Emerges from Stealth to Advance a New Class of Biologic Invented in Nobel Prize-Winning Computational Protein Design Lab. Retrieved October 30, 2024, from https://www.archon.bio/news/archon-biosciences-emerges-from-stealth-to-advance-a-new-class-of-biologic-invented-in-nobel-prize-winning-computational-protein-design-lab [2] Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders. Retrieved October 30, 2024, from https://www.prnewswire.com/news-releases/leal-therapeutics-announces-45-million-financing-to-progress-novel-therapies-for-patients-with-major-neurodegenerative-and-neuropsychiatric-disorders-302290936.html [3] Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies. Retrieved October 30, 2024, from https://www.prnewswire.com/news-releases/blue-earth-therapeutics-ltd-announces-completion-of-76-5m-series-a-financing-to-accelerate-development-of-next-generation-targeted-radioligand-therapies-302290606.html [4] Axonis Therapeutics Announces $115 Million Series A Financing. Retrieved October 30, 2024, from https://www.prnewswire.com/news-releases/axonis-therapeutics-announces-115-million-series-a-financing-302290888.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

Financing supports advancement of lead programs LTX-002 and LTX-001 to first-in-human trials WORCESTER, Mass., Oct. 30, 2024 /PRNewswire/ -- Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), today announced a $45 million financing. The round was led by Newpath Partners, with additional new investors Chugai Venture Fund and Alexandria Venture Investments, in addition to existing investors OrbiMed, Euclidean Capital and PhiFund. This latest financing round follows a previously disclosed $39 million financing. The proceeds will be used to advance Leal's pipeline of antisense oligonucleotide (ASO) and small molecule therapeutics for patients with CNS disorders. Leal's lead programs are LTX-002, an ASO for patients with genetic or sporadic amyotrophic lateral sclerosis (ALS), and LTX-001, a small molecule for patients with schizophrenia. The company plans to submit Investigational New Drug (IND) applications for LTX-002 and LTX-001 by the end of 2024 and commence first-in-human clinical trials in early 2025. Both programs address novel and well-characterized metabolic pathway targets that are dysregulated in disease states. "We are pleased to have the support from this leading group of both new and existing investors that share our vision for better therapeutics for people with neurodegenerative or neuropsychiatric disorders," said Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Leal. "This investment allows us to progress our lead programs in ALS and schizophrenia towards the clinic while also continuing our earlier-stage pipeline and platform development." In connection with the financing, Thomas Cahill, M.D., Ph.D., founder and managing partner of Newpath Partners, joined Leal's board of directors. Dr. Cahill said, "We are excited to support Leal as they progress their lead programs in ALS and schizophrenia, two CNS disorders with major unmet medical needs, towards the clinic." "We look forward to supporting this world-class team with deep expertise and proven track record in CNS therapeutics," said John Gustofson, head of Chugai Venture Fund. "Together with this strong syndicate, we are excited to help advance what we believe could be life-changing treatments for patients and their families." About Leal Therapeutics: Leal Therapeutics is a biotechnology company dedicated to developing novel precision medicines for patients with high-need central nervous system disorders. Leal was launched in 2021 and is headquartered in Worcester, Mass. About Newpath Partners: Newpath Partners is a life science and biotechnology venture firm dedicated to excellent science and to forming partnerships based on trust and a shared vision. Newpath is focused on creating companies that pioneer transformative therapeutics to mitigate suffering and death from disease. To learn more, visit . About Chugai Venture Fund: Chugai Venture Fund is a pioneering investment firm focused on fostering innovation and driving transformative advances in the life sciences industry. As a subsidiary of Chugai Pharmaceutical Co., Ltd., we leverage our parent company's extensive expertise and global presence to identify promising start-ups and cutting-edge technologies. Our mission is to help entrepreneurs and visionary teams realize their breakthrough ideas and ultimately contribute to the betterment of healthcare and society. By providing strategic funding, mentorship and access to resources, we aim to create a collaborative ecosystem that accelerates the development and commercialization of breakthrough therapies and medical solutions. To learn more, please visit . SOURCE Leal Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Plus, news about Zai Lab, Spero Therapeutics and EyePoint Pharmaceuticals: Leal Therapeutics raises $45M: The biotech, which emerged from stealth earlier this year, said the financing was led by Newpath Partners. Other investors included Chugai Venture Fund and OrbiMed. It’s developing CNS treatments, with plans to file INDs for two therapies by the end of this year. — Jaimy Lee SynOx raises $17M in Series B extension: The UK biotech plans to use the funds to support a Phase 3 test of its monoclonal antibody, called emactuzumab, in tenosynovial giant cell tumor, a form of rare, non-malignant growth. SynOx has already dosed the first few patients in the trial. The extension brings the company’s total Series B proceeds to $92 million. — Ayisha Sharma Zai Lab passes Phase 3 test for KarXT in China: Bristol Myers Squibb’s schizophrenia drug appears poised to reach the Chinese market after partner Zai Lab reported positive Phase 3 data there . A Phase 3 bridging study met the primary endpoint, demonstrating a statistically significant 9.2 reduction in a measurement of schizophrenia symptoms compared to placebo. — Max Bayer Spero fails proof-of-concept Phase 2a trial, lays off staff: The company ended development of the asset after an interim analysis of SPR720 found it did not meet the primary endpoints of a mid-stage trial for patients with nontuberculous mycobacterial pulmonary disease. Spero said the drug did not show “sufficient separation from placebo” and potential dose-limiting issues at the 1,000 mg dose level, exemplified by three grade 3 cases of hepatotoxicity that were eventually reversed. The company, which had 46 employees as of Dec. 31, is now laying off 39% of its workers. — Max Bayer EyePoint upsized its public offering. It now expects to raise $140 million instead of $100 million . — Jaimy Lee